Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pharmaceutical industry trends: 2023 outlook

By Noel Maestre | December 12, 2022

gene editing

[Gene editing image courtesy: Illustration by Jill George using images from the National Human Genome Research Institute & the National Institute of Allergy and Infectious Diseases]

If your only tool is a hammer, everything looks like a nail. Such was the state of the pharmaceutical industry a decade ago. Gone are the days of pharmaceutical companies predominantly specializing in single modalities such as traditional vaccines, monoclonal antibodies, plasma-derived therapies or small molecules. Today’s Big Pharma, fueled by the acquisition of countless startup companies, are ensuring their toolboxes are flush with the trusty tools of the past decades. In addition, Big Pharma companies are leveraging the power of new tools in the form of advanced therapeutic modalities. Consequently, the pipelines of leading companies in the pharmaceutical industry are increasingly comprised of complex new modalities such as cell therapies, mRNA, non-coding RNAs (ex., oligonucleotides and siRNA) and various gene therapies.

These new therapies lead to significant advancements for patients and, in some instances, carry the promise of a cure administered in a single dose. Several of these products are now on the market, including CSL’s hemophilia B gene therapy leading the pack at $3.5 million per patient, topping Bluebird’s CALD and beta-thalassemia or Novartis’ SMA gene therapy asking prices of $3.0, $2.8 and $2.0 million respectively, making it the world’s most expensive treatment. Steep asking price – yes, but not compared to the lifetime cost of medical care for these patients, which can be anywhere from two to more than 10 times the cost over the course of the patient’s lifespan.

Despite the incredible therapeutic benefit, these drugs have yet to convert into financial successes. Most are still targeting rare genetic diseases and small patient populations. In addition, the nature of single-dose curative treatments means pharmaceutical companies are likely to set incredibly high prices as their only way to recoup the development costs that go into producing these therapies. However, insurance companies have unsurprisingly balked at the huge price tags. In April 2022, the FDA approved Kite’s Yescarta for second-line treatment of large B-cell Lymphoma, marking an important milestone for the novel therapies to move up the treatment plan, potentially benefiting a broader patient population.

Novel modalities are on the rise in the pharmaceutical industry, but their financial impact on the industry has yet to provide the needed boost to put them on the map. In 2021, Comirnaty and Spikevax (the novel mRNA vaccine technologies) exploded on the scene, taking the number 1 and number 3 sales spots. But the top 100 product sales are still dominated by small molecules, monoclonal antibodies and traditional vaccines, with novel therapies barely breaking the top 200.

The potential to transform patients’ lives is turning the corner. Science is moving faster than our healthcare system. A swift change is needed to ensure that our financial system does not become the bottleneck, impeding patients’ ability to access the best treatment available; and pharmaceutical companies’ ability to leverage financial success to fuel the development of more miracle drugs. There is no doubt this breakthrough is coming soon; there are too many more promising drugs in the pipeline, which will inevitably force the system to adapt. The future is full of promise and undoubtedly multimodal.

Noel Maestre is the vice president, life sciences at CRB. Maestre is CRB‘s biotech subject matter expert, emphasizing Advanced Therapy Medicinal Products (ATMPs). He has an extensive background in mechanical and process utilities engineering with experience in the life science industry. He specializes in the design, construction and startup of biotechnology, pharmaceutical and advanced technology facilities. Maestre is a graduate of Pennsylvania State University with a bachelor of science in mechanical engineering. 


Filed Under: Cell & gene therapy
Tagged With: pharmaceutical industry
 

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE